Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors

CHING-YAO YANGWEI-YU LIAOCHAO-CHI HOKUAN-YU CHENTZU-HSIU TSAICHIA-LIN HSUKANG-YI SUYIH-LEONG CHANGCHEN-TU WUChia-Chi HsuBIN-CHI LIAOWei-Hsun HsuJIH-HSIANG LEECHIA-CHI LINJIN-YUAN SHIHCHIH-HSIN YANGCHONG-JEN YU2020-03-072020-03-0720200959-8049https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075197555&doi=10.1016%2fj.ejca.2019.10.019&partnerID=40&md5=391f584152d33a462097b5a001f16015https://scholars.lib.ntu.edu.tw/handle/123456789/473724[SDGs]SDG3epidermal growth factor receptor; programmed death 1 ligand 1; protein tyrosine kinase inhibitor; CD274 protein, human; EGFR protein, human; epidermal growth factor receptor; programmed death 1 ligand 1; protein kinase inhibitor; adult; aged; Article; cancer prognosis; cancer resistance; cancer survival; clinical outcome; cohort analysis; controlled study; drug efficacy; female; gene mutation; human; immunohistochemistry; lung adenocarcinoma; major clinical study; male; priority journal; progression free survival; protein expression; protein expression level; retrospective study; Taiwanese; tumor microenvironment; biosynthesis; genetics; immunology; lung adenocarcinoma; lung tumor; middle aged; mutation; pathology; tumor microenvironment; very elderly; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; B7-H1 Antigen; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Tumor MicroenvironmentAssociation between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitorsjournal article10.1016/j.ejca.2019.10.019317603102-s2.0-85075197555